Plus therapeutics completes sixth dosing cohort in respect™ glioblastoma trial

Austin, texas, dec. 15, 2020 (globe newswire) -- p lus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the respect™ phase 1 clinical trial evaluating the company's lead investigational asset, rhenium nanoliposome (rnl™), in patients with recurrent glioblastoma (gbm).
PSTV Ratings Summary
PSTV Quant Ranking